

Appendix 2 Further characteristics of randomised controlled trials of varenicline 1mg twice daily vs placebo included in the systematic review [posted as supplied by author]

First author	Year of publication	Location	Population	% smokers	Sponsored by pharmaceutical company	Loss to follow up varenicline %	Loss to follow up placebo %
Anthenelli	2013	Bosnia and Herzegovina, Croatia, Germany, Hungary, Romania, Russian Federation, Spain, USA	smokers with stably treated current or past major depression and no recent cardiovascular disease	100	yes	4.7	4.8
Bolliger	2011	Brazil, Venezuela, Mexico, Colombia, Costa Rica, S Africa, Egypt, UAE, Lebanon, Saudi Arabia, Lebanon	smokers from general population	100	yes	3.6	3
Brandon	2011	USA	smokers from general population	100	no	17.9	7.4
Burstein	2006	USA	smokers from general population	100	yes	0	0
Chengappa	2014	USA	smokers with bipolar disorder	100	no	6.5	6.9
Cinciripini	2013	USA	smokers from general population	100	no	24.4	28.3
Ebbert	2011	USA	people who use smokeless tobacco	100 (smokeless) 4 (cigarette)	no	7.9	2.6
Evins	2014	USA	smokers with schizophrenia, schizoaffective disorder or bipolar disorder	100	no	7.5	10.6
Faessel	2009	USA and UK	Adolescent smokers	100	yes	0	0
Fagerstrom	2010	Norway, Sweden	users of smokeless tobacco from primary care clinics and those attending smoking cessation clinics	100 (smokeless) 0 (cigarette)	yes	4.2	2.8
Fatemi	2013	USA	smokers with schizophrenia or schizoaffective disorder	100	no	NA	NA
Garza	2011	USA	smokers from general population	100	yes	1.8	0
Gonzales	2006	USA	smokers from general	100	yes	21.9	20.6

First author	Year of publication	Location	Population	% smokers	Sponsored by pharmaceutical company	Loss to follow up varenicline %	Loss to follow up placebo %
Gonzales	2014	Australia, Belgium, Canada, Czech Republic, France, Germany, UK, USA	population smokers hoping to quit who had been previously treated with varenicline	100	yes	13.7	12.2
Hughes	2011	USA	smokers from the general population who were not quite ready to quit	100	no	28	31.5
Jorenby	2006	USA	smokers from general population	100	yes	13.7	16.1
Litten	2013	USA	people with DSM IV TR alcohol dependence	39	no	2	5.9
McClure	2013	USA	smokers from general population	100	no	53.7	56
McKee	2009	USA	heavy drinking smokers	100	no	NA	NA
Meszaros	2013	USA	schizophrenic patients and patients with schizoaffective disorder and co-occurring nicotine and alcohol dependence	100	no	60	60
Mitchell	2012	USA	heavy drinking smokers	100	no	45.2	35.7
Nakamura	2007	Japan	smokers from general population	100	yes	NA	NA
Niaura	2008	USA	smokers from general population	100	yes	27	28
Nides	2006	USA	smokers from general population	100	yes	NA	NA
Oncken	2006	USA	smokers from general population	100	yes	NA	NA
Plebani	2012	USA	people dependent on cocaine	NA	no	NA	NA
Plebani	2013	USA	people meeting DSM IV-TR criteria for alcohol dependence and reported drinking at least 12 out of last 30 days	42.5	no	NA	NA
Poling	2010	USA	treatment seeking opioid dependent subjects who are smokers	100	no	8	22

First author	Year of publication	Location	Population	% smokers	Sponsored by pharmaceutical company	Loss to follow up varenicline %	Loss to follow up placebo %
Rennard	2012	Argentina, Brazil, Canada, China, Czech Republic, France, Germany, Hungary, Italy, Mexico, Republic of Korea, Taiwan, UK, USA	smokers from research centres, private practice offices and research clinics	100	yes	1.8	6
Rigotti	2010	Argentina, Australia, Brazil, Canada, Czech Republic, Denmark, France, Germany, Greece, Mexico, Netherlands, Republic of Korea, Taiwan, UK, USA	smokers with stable documented cardiovascular disease	100	yes	3.9	3.1
Shim	2012	Korea	smokers and non-smokers with chronic schizophrenia who were clinically stable with less than moderate severity	50	no	NA	NA
Stein	2013	USA	methadone maintained opiate dependent smokers	100	no	16.1	22.2
Steinberg	2011	USA	hospitalised smokers	100	no	45	45
Tashkin	2011	USA, Spain, France, Italy	smokers with mild to moderate COPD	100	yes	15.6	16.1
Tonnesen	2013	Denmark	ex-smokers who reported >11 months abstinence from smoking and on long term NRT	0	no	2.9	4.4
Tonstad	2006	Canada, Czech Republic, Denmark, Norway, Swede, USA, UK	smokers from medical clinics	100	yes	6.6	9.1
Tsai	2007	Korea, Taiwan	smokers from general population	100	yes	1.6	0.8
Wang	2009	Thailand, China, Singapore	smokers from general population	100	yes	3	4.2
Weiner	2011	USA	smokers with schizophrenia and schizoaffective disorder	100	no	NA	NA
Williams	2007	USA, Australia	smokers from the general population	100	yes	10	15.1
Williams	2012	USA, Canada	smokers with	100	yes	7.2	7

First author	Year of publication	Location	Population	% smokers	Sponsored by pharmaceutical company	Loss to follow up varenicline %	Loss to follow up placebo %
Wong	2012	Canada	schizophrenia/schizoaffective disorder smokers from preoperative clinics who will undergo surgery in 8 to 30 days	100	no	4.6	4.4
Zesiewicz	2012	USA	people with spinocerebellar ataxia 3	0	no	0	10
Zhao	2011	USA	healthy, elderly non smokers	0	yes	NA	NA